Cargando…
Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass
Serum autoantibodies against the p53 protein (p53 AAb) were analysed with a newly developed enzyme-linked immunosorbent assay (ELISA) based on highly purified and renatured p53. In a hospital-based cohort study, preoperative sera from 113 patients with ovarian cancer, 15 patients with borderline tum...
Autores principales: | , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2000
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408792/ https://www.ncbi.nlm.nih.gov/pubmed/11044359 http://dx.doi.org/10.1054/bjoc.2000.1446 |
_version_ | 1782155708166307840 |
---|---|
author | Vogl, F D Frey, M Kreienberg, R Runnebaum, I B |
author_facet | Vogl, F D Frey, M Kreienberg, R Runnebaum, I B |
author_sort | Vogl, F D |
collection | PubMed |
description | Serum autoantibodies against the p53 protein (p53 AAb) were analysed with a newly developed enzyme-linked immunosorbent assay (ELISA) based on highly purified and renatured p53. In a hospital-based cohort study, preoperative sera from 113 patients with ovarian cancer, 15 patients with borderline tumours and 117 patients with benign tumours of the ovaries were studied. The prevalence of p53 AAb in patients with invasive cancer was 19% (21/113). No p53 AAb were found in patients with borderline lesions or benign tumours. The ELISA had a specificity for malignancy of 99% (1 of 117; false-positive from a patient with severe diabetes mellitus) and a likelihood ratio (LR+) for a positive test result of 21.7 (elevated CA125 and malignancy: LR+ 3.7). p53 AAb were only detectable in patients with immunohistochemical staining of nuclear p53 in the tumour (P= 0.006). Presence of p53 AAb positively correlated with tumour stage (P= 0.034) and grade (P= 0.009). Kaplan–Meier analysis showed both a shortened overall survival (P= 0.0016, log-rank) and relapse-free survival (P= 0.055) for p53 AAb-positive patients (median follow-up 22 months). High titres related to even worse prognosis. p53 AAb independently related to poor survival adjusting for stage (P= 0.026), grade (P= 0.029) and residual disease after surgery (P= 0.005). Preoperative findings of adnexal mass with serum p53 AAb are strongly suggestive of an aggressive invasive ovarian cancer. © 2000 Cancer Research Campaign |
format | Text |
id | pubmed-2408792 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2000 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-24087922009-09-10 Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass Vogl, F D Frey, M Kreienberg, R Runnebaum, I B Br J Cancer Regular Article Serum autoantibodies against the p53 protein (p53 AAb) were analysed with a newly developed enzyme-linked immunosorbent assay (ELISA) based on highly purified and renatured p53. In a hospital-based cohort study, preoperative sera from 113 patients with ovarian cancer, 15 patients with borderline tumours and 117 patients with benign tumours of the ovaries were studied. The prevalence of p53 AAb in patients with invasive cancer was 19% (21/113). No p53 AAb were found in patients with borderline lesions or benign tumours. The ELISA had a specificity for malignancy of 99% (1 of 117; false-positive from a patient with severe diabetes mellitus) and a likelihood ratio (LR+) for a positive test result of 21.7 (elevated CA125 and malignancy: LR+ 3.7). p53 AAb were only detectable in patients with immunohistochemical staining of nuclear p53 in the tumour (P= 0.006). Presence of p53 AAb positively correlated with tumour stage (P= 0.034) and grade (P= 0.009). Kaplan–Meier analysis showed both a shortened overall survival (P= 0.0016, log-rank) and relapse-free survival (P= 0.055) for p53 AAb-positive patients (median follow-up 22 months). High titres related to even worse prognosis. p53 AAb independently related to poor survival adjusting for stage (P= 0.026), grade (P= 0.029) and residual disease after surgery (P= 0.005). Preoperative findings of adnexal mass with serum p53 AAb are strongly suggestive of an aggressive invasive ovarian cancer. © 2000 Cancer Research Campaign Nature Publishing Group 2000-11 2000-10-26 /pmc/articles/PMC2408792/ /pubmed/11044359 http://dx.doi.org/10.1054/bjoc.2000.1446 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article Vogl, F D Frey, M Kreienberg, R Runnebaum, I B Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass |
title | Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass |
title_full | Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass |
title_fullStr | Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass |
title_full_unstemmed | Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass |
title_short | Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass |
title_sort | autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2408792/ https://www.ncbi.nlm.nih.gov/pubmed/11044359 http://dx.doi.org/10.1054/bjoc.2000.1446 |
work_keys_str_mv | AT voglfd autoimmunityagainstp53predictsinvasivecancerwithpoorsurvivalinpatientswithanovarianmass AT freym autoimmunityagainstp53predictsinvasivecancerwithpoorsurvivalinpatientswithanovarianmass AT kreienbergr autoimmunityagainstp53predictsinvasivecancerwithpoorsurvivalinpatientswithanovarianmass AT runnebaumib autoimmunityagainstp53predictsinvasivecancerwithpoorsurvivalinpatientswithanovarianmass |